FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4383199033> ?p ?o ?g. }

• W4383199033 endingPage "102060" @default.
• W4383199033 startingPage "102060" @default.
• W4383199033 abstract "BackgroundHistorically, survivors of common lymphoid neoplasms (LNs) had increased risks for therapy-related myelodysplastic syndrome/acute myeloid leukemia (tMDS/AML). Despite major treatment advances in the treatment of LNs over the last two decades, a comprehensive evaluation of tMDS/AML trends following both common and rare LNs treated in this contemporary period is lacking.MethodsIn US cancer registries during 2000–2018, we identified 1496 tMDS/AML cases among 186,503 adults who were treated with initial chemo/immunotherapy for first primary LN and survived ≥1 year. We quantified tMDS/AML standardized incidence ratios (SIRs), excess absolute risks (EARs, per 10,000 person-years), and cumulative incidence.FindingsThe highest tMDS/AML risks occurred after precursor leukemia/lymphoma (SIR = 39, EAR = 30), Burkitt leukemia/lymphoma (SIR = 20, EAR = 24), peripheral T-cell lymphoma (SIR = 12, EAR = 23), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL; SIR = 9.0, EAR = 27), and mantle cell lymphoma (SIR = 8.5, EAR = 25). Elevated risks (SIRs = 4.2–6.9, EARs = 4.9–15) also were observed after all other LN subtypes except hairy cell leukemia and mycosis fungoides/Sézary syndrome. Among patients treated more recently, tMDS/AML risks were significantly higher after CLL/SLL (SIR2000-2005 = 4.8, SIR2012-2017 = 10, Ptrend = 0.0043), significantly lower after Hodgkin (SIR2000-2005 = 15, SIR2012-2017 = 6.3, Ptrend = 0.024) and marginal zone (SIR2000-2005 = 7.5, SIR2012-2017 = 2.3, Ptrend = 0.015) lymphomas, and non-significantly lower after mantle cell lymphoma (SIR2000-2005 = 10, SIR2012-2017 = 3.2, Ptrend = 0.054), lymphoplasmacytic lymphoma/Waldenström macroglobulinemia (SIR2000-2005 = 6.9, SIR2012-2017 = 1.0, Ptrend = 0.067), and plasma cell neoplasms (SIR2000-2005 = 5.4, SIR2012-2017 = 3.1, Ptrend = 0.051). EAR and cumulative incidence trends generally were similar to SIR trends. Median survival after tMDS/AML was 8.0 months (interquartile range, 3.0–22.0).InterpretationAlthough tMDS/AML risks are significantly elevated after initial chemo/immunotherapy for most LNs, patients treated more recently have lower tMDS/AML risks, except after CLL/SLL. Though rare, the poor prognosis following tMDS/AML emphasizes the importance of continued efforts to reduce treatment-associated toxicity.FundingThis research was supported in part by the Intramural Research Program of the National Cancer Institute, National Institutes of Health. LMM, GMD, REC, and CBS verified the data, and all authors had access to the data and made the decision to submit for publication." @default.
• W4383199033 created "2023-07-06" @default.
• W4383199033 creator A5000437754 @default.
• W4383199033 creator A5002226361 @default.
• W4383199033 creator A5029411554 @default.
• W4383199033 creator A5043295901 @default.
• W4383199033 creator A5047405171 @default.
• W4383199033 creator A5048229229 @default.
• W4383199033 creator A5077697764 @default.
• W4383199033 creator A5091252684 @default.
• W4383199033 date "2023-07-01" @default.
• W4383199033 modified "2023-10-14" @default.
• W4383199033 title "Trends in risk for therapy-related myelodysplastic syndrome/acute myeloid leukemia after initial chemo/immunotherapy for common and rare lymphoid neoplasms, 2000–2018" @default.
• W4383199033 cites W175983422 @default.
• W4383199033 cites W1834572928 @default.
• W4383199033 cites W1891896135 @default.
• W4383199033 cites W1964462241 @default.
• W4383199033 cites W1966724636 @default.
• W4383199033 cites W1973617793 @default.
• W4383199033 cites W1987173571 @default.
• W4383199033 cites W1993691917 @default.
• W4383199033 cites W2004799731 @default.
• W4383199033 cites W2017744478 @default.
• W4383199033 cites W2061918976 @default.
• W4383199033 cites W2066689762 @default.
• W4383199033 cites W2070728536 @default.
• W4383199033 cites W2131853861 @default.
• W4383199033 cites W2138210947 @default.
• W4383199033 cites W2140651954 @default.
• W4383199033 cites W2143351780 @default.
• W4383199033 cites W2168227471 @default.
• W4383199033 cites W2168653495 @default.
• W4383199033 cites W2188652142 @default.
• W4383199033 cites W2338057729 @default.
• W4383199033 cites W2339658711 @default.
• W4383199033 cites W2518731208 @default.
• W4383199033 cites W2749642104 @default.
• W4383199033 cites W2784038263 @default.
• W4383199033 cites W2906323921 @default.
• W4383199033 cites W2911188335 @default.
• W4383199033 cites W2963300099 @default.
• W4383199033 cites W2964331258 @default.
• W4383199033 cites W2992414472 @default.
• W4383199033 cites W3009142496 @default.
• W4383199033 cites W3134284079 @default.
• W4383199033 cites W3135149373 @default.
• W4383199033 cites W3154879798 @default.
• W4383199033 cites W3162465133 @default.
• W4383199033 cites W3164945147 @default.
• W4383199033 cites W3165108019 @default.
• W4383199033 cites W3167992592 @default.
• W4383199033 cites W3168603280 @default.
• W4383199033 cites W4297311824 @default.
• W4383199033 cites W4307647274 @default.
• W4383199033 cites W4311286848 @default.
• W4383199033 cites W4366984620 @default.
• W4383199033 cites W4379505350 @default.
• W4383199033 doi "https://doi.org/10.1016/j.eclinm.2023.102060" @default.
• W4383199033 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37457112" @default.
• W4383199033 hasPublicationYear "2023" @default.
• W4383199033 type Work @default.
• W4383199033 citedByCount "0" @default.
• W4383199033 crossrefType "journal-article" @default.
• W4383199033 hasAuthorship W4383199033A5000437754 @default.
• W4383199033 hasAuthorship W4383199033A5002226361 @default.
• W4383199033 hasAuthorship W4383199033A5029411554 @default.
• W4383199033 hasAuthorship W4383199033A5043295901 @default.
• W4383199033 hasAuthorship W4383199033A5047405171 @default.
• W4383199033 hasAuthorship W4383199033A5048229229 @default.
• W4383199033 hasAuthorship W4383199033A5077697764 @default.
• W4383199033 hasAuthorship W4383199033A5091252684 @default.
• W4383199033 hasBestOaLocation W43831990331 @default.
• W4383199033 hasConcept C126322002 @default.
• W4383199033 hasConcept C143998085 @default.
• W4383199033 hasConcept C2777525834 @default.
• W4383199033 hasConcept C2777756187 @default.
• W4383199033 hasConcept C2777938653 @default.
• W4383199033 hasConcept C2778461978 @default.
• W4383199033 hasConcept C2778729363 @default.
• W4383199033 hasConcept C2779338263 @default.
• W4383199033 hasConcept C2780007613 @default.
• W4383199033 hasConcept C2780653079 @default.
• W4383199033 hasConcept C2780817109 @default.
• W4383199033 hasConcept C2781214270 @default.
• W4383199033 hasConcept C2911091166 @default.
• W4383199033 hasConcept C71924100 @default.
• W4383199033 hasConcept C88879693 @default.
• W4383199033 hasConceptScore W4383199033C126322002 @default.
• W4383199033 hasConceptScore W4383199033C143998085 @default.
• W4383199033 hasConceptScore W4383199033C2777525834 @default.
• W4383199033 hasConceptScore W4383199033C2777756187 @default.
• W4383199033 hasConceptScore W4383199033C2777938653 @default.
• W4383199033 hasConceptScore W4383199033C2778461978 @default.
• W4383199033 hasConceptScore W4383199033C2778729363 @default.
• W4383199033 hasConceptScore W4383199033C2779338263 @default.
• W4383199033 hasConceptScore W4383199033C2780007613 @default.
• W4383199033 hasConceptScore W4383199033C2780653079 @default.
• W4383199033 hasConceptScore W4383199033C2780817109 @default.

• next